Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2023202220212020 May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Next page › Last page » Displaying 13 - 24 of 60 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2023202220212020 May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview March 2, 2022 Protara Therapeutics to Participate in Upcoming Investor Conferences February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer January 4, 2022 Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Next page › Last page » Displaying 13 - 24 of 60
May 5, 2022 Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
March 24, 2022 Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
March 9, 2022 Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview
February 1, 2022 Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
January 10, 2022 Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
November 4, 2021 Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
